U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to lower prices of their ...

By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition ...

Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

We sold Novo Nordisk out of the portfolio due to two concerns that made us question the company’s ability to deliver ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

The companies announced a huge deal that will have implications for investors. Eli Lilly ( LLY 1.39%) and Novo Nordisk ( NVO ...

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...